A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the Pharmacokinetics of Three SC Olanzapine Extended-Release Formulations With Different Release Rates Following Single Administration in Participants With Schizophrenia or Schizoaffective Disorder
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Olanzapine (Primary) ; Olanzapine
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Teva Branded Pharmaceutical Products R&D
Most Recent Events
- 14 Feb 2025 Status changed from active, no longer recruiting to completed.
- 27 Dec 2024 Planned End Date changed from 11 Dec 2024 to 15 Jan 2025.
- 27 Dec 2024 Planned primary completion date changed from 11 Dec 2024 to 15 Jan 2025.